Helping your patients be prepared with an anaphylaxis action plan is an important part of managing the risk of a life-threatening allergic reaction.¹

For your patients at increased risk, being prepared means¹ :

• Avoiding known allergens
• Knowing what symptoms to watch for
• Using an EPIPEN^® (epinephrine injection, USP) Auto-Injector (or its authorized generic) if a life-threatening (severe) allergic reaction occurs
• Getting emergency medical help right away

It is important to communicate to your patients that if they, their child or someone they’re caring for shows signs or symptoms of an anaphylactic reaction, they should inject EPIPEN or EPIPEN JR^® (epinephrine injection, USP) Auto-Injector—or their authorized generics—immediately and seek emergency medical attention.^2,5

After administering an initial dose of epinephrine, the NIAID Expert Panel recommends transfer to an emergency facility for observation (4-6 hours or longer, depending on severity of the reaction) and possible further treatment.¹ More than two sequential doses of epinephrine should be administered only under direct medical supervision.^2,3

Because anaphylaxis symptoms may progress rapidly and become life threatening, it is important that treatment with epinephrine be initiated promptly.^5-7

According to guidelines developed by the National Institute of Allergy and Infectious Diseases (NIAID) Expert Panel, treatment for food-induced anaphylaxis should focus on¹ :

• Prompt and rapid treatment after onset of symptoms
• Intramuscular (IM) epinephrine as first-line therapy
• Other treatments, which are adjunctive to epinephrine dosing

The Expert Panel recommends that initial management begin with the following concurrent steps¹ :

• Elimination of additional allergen exposure
• IM injection of epinephrine
• Call for help (911 or equivalent) after administering epinephrine

According to the NIAID Expert Panel, “Epinephrine is the first-line treatment in all cases of anaphylaxis. All other drugs have a delayed onset of action.”¹

In cases of suboptimal response to the initial dose of epinephrine, or if symptoms progress, the NIAID Expert Panel recommends repeat epinephrine dosing as first-line therapy over adjunctive treatments.¹

NIAID food allergy guidelines recommend at-risk patients have access to two epinephrine auto-injectors.¹ More than two sequential doses of epinephrine should only be administered under medical supervision.^2,3

1. 20% of patients may need a second dose due to ongoing symptoms^1,4

6.3.1.1 Epinephrine—first-line treatment
“If a patient responds poorly to the initial dose or has ongoing or progressive symptoms despite initial dosing, repeated dosing may be required after 5 to 15 minutes. Reports of patients receiving epinephrine for food-induced or non-food-induced anaphylaxis note that as high as 10%-20% of individuals who receive epinephrine will require more than 1 dose before recovery of symptoms.^”1

2. 20% of patients may experience a biphasic reaction¹

6.2.3 Time course of food-induced anaphylaxis
“A biphasic reaction includes a recurrence of symptoms that develops after apparent resolution of the initial reaction. Biphasic reactions have been reported to occur in 1%-20% of anaphylaxis episodes and typically occur about 8 hours after the first reaction, although recurrences have been reported up to 72 hours later.^”1

A 2014 survey of caregivers and patients with reported anaphylaxis showed that 36% planned to use an antihistamine to treat future episodes of anaphylaxis, despite the fact that antihistamines are not indicated to treat the life-threatening symptoms of anaphylaxis.^1,9

Antihistamines do not relieve shortness of breath, wheezing, gastrointestinal symptoms or shock. Therefore, antihistamines should be considered adjunctive therapy and should not be substituted for epinephrine.¹

According to the NIAID guidelines, use of antihistamines is the most common reason reported for not using epinephrine and may place a patient at a significantly increased risk for progression toward a life-threatening reaction.¹